Quick Answer
International Stem Cell CORP reported Cash and Equivalents of $304.0 thousand for fiscal year 2017.
International Stem Cell CORP Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2017 | $304.0K | +176.4% |
| 2016 | $110.0K | -79.3% |
| 2015 | $532.0K | -52.1% |
| 2014 | $1.11M | -50.5% |
| 2013 | $2.24M | +243.0% |
| 2012 | $654.0K | -51.1% |
| 2011 | $1.34M | -76.9% |
| 2010 | $5.78M | +695.3% |
| 2009 | $727.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2017 | $510.0K | -30.4% | +0.0% |
| June 30, 2017 | $510.0K | -30.4% | -24.6% |
| March 31, 2017 | $676.0K | -56.2% | +514.5% |
| December 31, 2016 | $110.0K | -79.3% | -85.0% |
| September 30, 2016 | $733.0K | +22.4% | +0.0% |
| June 30, 2016 | $733.0K | +32.3% | -52.5% |
| March 31, 2016 | $1.54M | +152.4% | +189.8% |
| December 31, 2015 | $532.0K | -52.1% | -11.2% |
- International Stem Cell CORP showed an increase of +176.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2017 period, International Stem Cell CORP’s cash and equivalents has declined by 58.2% (from $727.0 thousand to $304.0 thousand).
- The most recent figure is from International Stem Cell CORP’s fiscal year 2017 report (Form 10-K), filed with the SEC on April 9, 2018.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: